You are here: Industry Insights > Bristol-Myers Squibb

News List

BMS faces lawsuit from Celgene shareholders over missed deadline for Breyanzi approval firstwordpharma
June 04, 2021
Celgene's former shareholders sued Bristol Myers Squibb in US court on Thursday claiming that the drugmaker failed to use its best efforts to secure FDA approval of Breyanzi (lisocabtagene maraleucel) by the end of 2020
Empliciti, Revlimid combo falls short in multiple myeloma pharmatimes
March 12, 2020
Bristol-Myers Squibb has revealed that Empliciti (elotuzumab), when added to BMS/Celgene’s Revlimid (lenalidomide) and dexamethasone, has not proved successful in extending the time patients with newly-diagnosed myeloma who were ineligible for ...
Opdivo, cabiralizumab combo falls short in pancreatic cancer pharmatimes
March 10, 2020
Bristol-Myers Squibb has revealed that its Phase II trial testing the combination of cabiralizumab with Opdivo (nivolumab) with and without chemotherapy in patients with advanced pancreatic cancer has fallen short of success.
Opdivo/Yervoy continues to impress in kidney cancer pharmatimes
March 10, 2020
Bristol-Myers Squibb has announced that its Opdivo (nivolumab) and Yervoy (ipilimumab) combo has demonstrated superior overall survival, complete response rates and objective response rates at 42 months ...
Voluntis and Bristol-Myers Squibb to co-develop digital therapeutics for oncology worldpharmanews
March 05, 2020
Voluntis, a leader in digital therapeutics, and Bristol-Myers Squibb Company announced a collaboration agreement to create and investigate digital therapeutic solutions that will support cancer patients.
Bristol-Myers Squibb completes divestment of manufacturing facility in Anagni, Italy worldpharmanews
January 09, 2020
Bristol-Myers Squibb Company (NYSE:BMY) announced today that it has completed its previously announced divestment of its oral solid, biologics, and sterile product manufacturing and ...
WindMIL Announces Collaboration with Bristol-Myers Squibb to Evaluate MILs, Opdivo Combination americanpharmaceuticalreview
December 20, 2019
WindMIL Therapeutics has entered into a new clinical research collaboration with Bristol-Myers Squibb Company to evaluate the safety and efficacy of ...
Vedanta Biosciences initiates first-in-patient study of VE800 in combination with Bristol-Myers Squibb’s Opdivo pharmaceutical-business-review
December 16, 2019
Vedanta Biosciences announced the initiation of a first-in-patient clinical study of VE800 in combination with Bristol-Myers Squibb's programmed death-1 (PD-1) immune ...
Bristol-Myers Squibb’s Liso-Cel meets key endpoints in blood cancer trial pharmaceutical-business-review
December 11, 2019
Bristol-Myers Squibb announced that its blood cancer treatment lisocabtagene maraleucel (liso-cel) has achieved its primary and secondary endpoints in TRANSCEND NHL 001 study.
U.S. Food and Drug Administration Accepts for Priority Review Bristol-Myers Squibb’s Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab) Combination for Patients with Previously Treated Advanced Hepatocellular Carcinoma En-CPhI.CN
November 13, 2019
The FDA also granted Opdivo plus Yervoy Breakthrough Therapy Designation for this potential indication.

Previous page 1 2 3 4 5 6 7 8 9 10 Next page